Xencor Inc (XNCR)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Bassil I. Dahiyat |
| Employees: | 280 |
| Web site: | xencor.com |
|
465 N. HALSTEAD ST., SUITE 200, PASADENA, CA, 91107
626-305-5900
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.
Please log in first to see chart